The Cell & Gene Therapy (CGT) Deals, Funding & Investments Dashboard provides a complete view of the financial ecosystem driving the next generation of advanced therapies. It tracks venture funding, strategic partnerships, licensing agreements, acquisitions, and company-level investment activity to help pharma leaders, biotech companies, investors, and strategy teams understand where capital is moving and which technologies are gaining market confidence.
Instead of looking only at market growth, this dashboard reveals the business signals behind CGT innovation — showing which companies are attracting investments, which technologies are receiving funding, and where future market opportunities are emerging.
1. CGT Funding Landscape: Tracking Where Capital Is Moving
Investment activity is one of the strongest indicators of market confidence. The CGT industry has attracted billions of dollars as companies develop advanced platforms across CAR-T therapy, gene editing, rare disease treatments, and next-generation manufacturing technologies.
The dashboard tracks:
- Total funding raised by CGT companies
- Funding rounds (Seed, Series A, B, C, IPO)
- Venture capital activity
- Private investments
- Funding growth trends
- Leading investors
For decision makers, this provides visibility into:
Which technologies are attracting investor attention and which companies are positioned for future growth.
2. Strategic Deals & Partnerships: Understanding Pharma Expansion
Large pharmaceutical companies are increasingly partnering with biotech companies to access innovative CGT platforms and accelerate their pipelines.
The dashboard captures:
- Licensing agreements
- Co-development partnerships
- Research collaborations
- Technology access deals
- Strategic alliances
These deals indicate where major industry players see future value.
Example:
Novartis AG: A Major CGT Investment Story
Novartis became one of the early leaders in commercial CAR-T therapy through its investment in cell therapy innovation.
In 2012, Novartis entered a major collaboration with University of Pennsylvania to develop CAR-T technology using research from Carl June and his team.
This partnership helped create Kymriah, which became the first FDA-approved CAR-T therapy in 2017 for certain blood cancers.
The deal represented a major shift:
From:
“Research-stage cell therapy technology”
To:
“Commercially approved billion-dollar therapeutic platform”
3. Company Investment Intelligence: Example Analysis — CRISPR Therapeutics: Turning Gene Editing Innovation Into Commercial Success
A company-level view helps investors, pharma leaders, and strategy teams understand how scientific innovation, funding, and partnerships create value in the Cell & Gene Therapy ecosystem.
CRISPR Therapeutics is one of the strongest examples of how a biotechnology company can transform a breakthrough technology into a commercially successful advanced therapy business.
Founded in 2013, the company focuses on CRISPR/Cas9 gene editing technology to develop treatments for genetic diseases, cancer, and other complex conditions.
Its growth journey shows how the combination of innovation, investment, and strategic partnerships can accelerate CGT development.
Funding & Growth Journey
In its early years, CRISPR Therapeutics attracted strong investor interest due to the potential of gene editing to create long-term treatment solutions.
The company raised private funding to support:
- Gene-editing research
- Clinical development programs
- Manufacturing capabilities
- Regulatory preparation
In 2016, CRISPR Therapeutics completed its Nasdaq IPO and raised approximately $56 million, helping the company expand its clinical pipeline and development activities.
Strategic Partnership With Vertex Pharmaceuticals
A major milestone came through its partnership with Vertex Pharmaceuticals for developing Casgevy (exa-cel), a CRISPR-based therapy.
The collaboration included:
- Approximately $105 million upfront payment
- Potential milestone payments
- Joint development strategy
- Commercialization support
This partnership combined CRISPR Therapeutics’ gene-editing expertise with Vertex’s clinical and commercialization capabilities, reducing development risk and accelerating market entry.
2023 Commercial Breakthrough: First CRISPR-Based Approved Therapy
CRISPR Therapeutics achieved a historic milestone when Casgevy became the first approved CRISPR-based medicine.
Regulatory approvals:
- UK approval — November 2023
- FDA approval — December 2023
The therapy targets:
- Sickle cell disease
- Transfusion-dependent beta thalassemia
This approval proved that gene editing could move from research laboratories to real-world patient treatment.
Strategic Importance for CGT Market
CRISPR Therapeutics demonstrates the complete CGT growth model:
Scientific Innovation → Development of CRISPR technology
Investment Capital → Funding research and clinical trials
Strategic Partnerships → Faster commercialization
Regulatory Success → Market validation
The company continues expanding into areas such as oncology, immune cell therapies, and genetic disorders.
The dashboard tracks similar company journeys to help decision makers identify:
- High-potential CGT companies
- Major investment trends
- Strategic partnerships
- Emerging technologies shaping the future of advanced therapies
Why Leaders Need This Dashboard
The CGT market is moving quickly, with new partnerships, funding rounds, and acquisitions reshaping competitive positions.
The CGT Deals, Funding & Investments Dashboard helps leaders monitor:
- Who is investing
- Where funding is flowing
- Which companies are growing
- Which technologies are gaining momentum
- Where partnership opportunities exist
This is not just a funding tracker — it is a strategic intelligence platform designed to help decision makers understand the financial movements shaping the future of Cell & Gene Therapy.
CGT Dashboard Access
Track the rapidly evolving Cell & Gene Therapy landscape with insights on 1,300+ companies, including industry leaders such as Novartis, Bristol Myers Squibb, Vertex Pharmaceuticals, and CRISPR Therapeutics. Our dashboard brings together pipeline intelligence, clinical developments, manufacturing capabilities, investments, partnerships, and competitive insights in one place, helping decision makers identify opportunities and stay ahead in the CGT market.
Get CGT Dashboard Access Easily: https://www.towardshealthcare.com/cell-gene-intelligence-platform